咪唑斯汀与西替利嗪治疗慢性荨麻疹的药物经济学分析  

Pharmacoeconomic analysis of mizolastine and cetirizine in treatment of chronic urticaria

作　　者：胡德建[1] 李勇剑[1] 肖璇[2] 

机构地区：[1]山东省潍坊市人民医院药剂科,261041 [2]中国药科大学药学院

出　　处：《中国医药》2012年第3期331-332,共2页China Medicine

摘　　要：目的比较咪唑斯汀与西替利嗪治疗慢性荨麻疹的成本。效果（C／E）。方法96例慢性荨麻疹患者随机分为A组和B组，分别口服咪唑斯汀和西替利嗪14d，1次／d，10mg／次，比较2组临床疗效以及运用药物经济学方法进行C／E分析。结果A、B2组的总有效率分别为66．67％（32例）和64．58％（31例），差异无统计学意义（P〉0．05）；B组的C／E（0．22）明显低于A组（0．85），差异有统计学意义（P〈0．05）。结论西替利嗪治疗荨麻疹的C／E较低，较咪唑斯汀更适宜临床推广使用。Objective To evaluate the cost-effectiveness （C/E） of mizolastine and cetirizine in treatment of chronic urticaria. Methods Ninety-six cases with chronic urticaria were randomized into group A and group B. They were administered with mizolastine and cetirizine for 14 d, qd, 10 mg/time, respectively. The curative effects were observed and C/E analysis was made by cost economics approach. Results The total effective rates of group A and group B were 66. 67% and 64. 58% , respectively. There were no significant differences in total effective rates between the two groups （P 〉 0. 05）. The C/E of group B （0. 22） was significantly lower than that of group A （0. 85 ）. The difference between the two groups had a statistical significance （ P 〈 0. 05 ）. Conclusion The C / E of cetirizine is low in treatment of chronic urticaria.

关 键 词：慢性荨麻疹 咪唑斯汀 西替利嗪 成本一效果分析 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]